# STK11 (LKB1): AMP-Activated Protein Kinase (AMPK) Activation, Metabolic Checkpoints, and Peutz-Jeghers ## Key Takeaways - STK11 (LKB1) is a master upstream kinase essential for activating AMP-activated protein kinase (AMPK) and 13 other AMPK-related kinases (ARKs), governing cellular energy homeostasis, polarity, and growth control. - Germline loss-of-function mutations in STK11 cause Peutz-Jeghers syndrome (PJS), characterized by hamartomatous polyposis and a significantly elevated risk of multiple epithelial malignancies. - Somatic inactivation of STK11 is a recurrent event in sporadic cancers, notably non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma, and cervical carcinoma, driving metabolic reprogramming and immune evasion. - STK11 mutations are associated with resistance to chemotherapy and immune checkpoint inhibitors (ICIs), particularly in KRAS-mutant NSCLC, necessitating the development of novel therapeutic strategies targeting metabolic vulnerabilities or downstream effectors. - The functional unit of LKB1 is a heterotrimeric complex with STRAD and MO25, which is crucial for its catalytic activity, cytoplasmic localization, and proper substrate recognition. - STK11-mutant tumors exhibit a distinct immunosuppressive tumor microenvironment, characterized by reduced T-cell infiltration and impaired interferon signaling, contributing to therapeutic resistance. --- ## Executive Summary & Key Metadata Serine/threonine kinase 11 (STK11), universally designated as Liver Kinase B1 (LKB1), is a master upstream kinase that orchestrates cellular energy homeostasis, polarity, and growth control. Germline loss-of-function mutations in STK11 are the principal genetic drivers of Peutz-Jeghers syndrome (PJS), an autosomal dominant disorder characterized by hamartomatous polyposis, mucocutaneous pigmentation, and a markedly elevated lifetime risk of multiple epithelial malignancies [1, 2, 3]. Somatic inactivation of STK11 is a recurrent event in sporadic cancers, most prominently in non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma, and cervical carcinoma, where it drives metabolic reprogramming, immune evasion, and therapeutic resistance [1, 4, 5, 6]. The STK11 gene product is a 433-amino-acid serine/threonine kinase that functions as the primary activating kinase for AMP-activated protein kinase (AMPK) and 13 other AMPK-related kinases (ARKs). Through these downstream effectors, LKB1 governs a broad spectrum of cellular processes, including energy stress responses, cell cycle arrest, apoptosis, cell polarity, and metabolic checkpoint control. The enzyme operates within a heterotrimeric complex with the pseudokinase STRAD (STE20-related kinase adaptor) and the scaffolding protein MO25 (mouse protein 25), a configuration essential for its catalytic activity and cytoplasmic localization [1, 2, 5]. This reference manual provides an exhaustive, publication-grade analysis of STK11, integrating genomic architecture, structural biology, signaling networks, clinical pathology, [pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), and bioinformatic resources. | **Metadata Field** | **Value** | |---|---| | HGNC Symbol | STK11 | | UniProt Accession | Q15831 | | Representative PDB ID | 2W5A | | Chromosomal Locus | 19p13.3 | | Primary Molecular Function | Serine/threonine kinase; master activator of AMPK and AMPK-related kinases | | Disease & Pathology Associations | Peutz-Jeghers syndrome; NSCLC; pancreatic cancer; cervical cancer; melanoma; breast cancer | | NCBI Gene ID | 6794 | | Ensembl ID | ENSG00000118046 | | OMIM | 602216 | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The STK11 gene is located on the short arm of chromosome 19 at cytogenetic band 19p13.3, a region frequently subject to loss of heterozygosity (LOH) in sporadic tumors [2, 3, 4]. The gene spans approximately 23 kilobases of genomic DNA and comprises 10 exons, with the translation initiation codon located in exon 1 and the termination codon in exon 10. The coding sequence is 1,302 nucleotides in length, encoding a 433-amino-acid protein with a predicted molecular mass of approximately 48.6 kDa [5, 6]. The genomic organization of STK11 is notable for its compactness and the presence of a large 5' untranslated region (UTR) that contains multiple regulatory elements. The promoter region lacks a canonical TATA box but contains a high GC content, characteristic of housekeeping genes. Functional promoter analysis has identified a core promoter region spanning nucleotides -100 to +50 relative to the transcription start site, which contains binding sites for the transcription factor p53 [1]. This p53-responsive element is functionally significant, as DNA damage-induced p53 activation leads to transcriptional upregulation of STK11, establishing a tumor-suppressive feedback loop [1]. ### 1.2 Promoter Architecture and Transcriptional Regulation The transcriptional regulation of STK11 is complex and cell-type-specific. The core promoter contains multiple Sp1 binding sites, which are essential for basal transcriptional activity. Bioinformatics analysis of the STK11 promoter has revealed conserved binding motifs for several transcription factors, including AP-1, NF-κB, and CREB [2, 6]. The presence of these elements suggests that STK11 expression is responsive to diverse cellular stress signals and metabolic cues. The p53-mediated regulation of STK11 transcription is particularly significant in the context of cancer biology. Yao and colleagues demonstrated that p53 binds directly to the STK11 promoter and activates its transcription in response to genotoxic stress [1]. This regulatory axis creates a positive feedback loop wherein p53 activation leads to increased LKB1 expression, which in turn activates AMPK and promotes cell cycle arrest and apoptosis. Disruption of this loop, either through p53 mutation or STK11 promoter hypermethylation, contributes to tumorigenesis. ### 1.3 Alternative Splicing and Isoform Diversity Alternative splicing of STK11 generates multiple transcript variants with distinct functional properties. The canonical transcript (NM_000455) encodes the full-length 433-amino-acid kinase. However, several alternatively spliced isoforms have been characterized: **Mitochondrial Isoform (LKB1-M):** A novel exon 1b within intron 1 generates a mitochondria-targeted LKB1 variant found exclusively in higher-order primates [3]. This isoform contains an N-terminal mitochondrial localization signal and is imported into the mitochondrial matrix, where it may regulate mitochondrial metabolism and apoptosis. The exonization of this alternative first exon is mediated by Alu-Sc elements, representing a primate-specific evolutionary innovation [3]. **Truncated Isoforms:** Several PJS-associated splice variants have been identified, including the STK11 c.597⁁598insIVS4 isoform, which results from aberrant splicing and introduces a premature termination codon [4]. These truncated isoforms typically lack the C-terminal regulatory domain and exhibit dominant-negative or loss-of-function properties. **Rodent Isoforms:** The mouse Stk11 gene also produces alternatively spliced variants, with a differentially expressed transcript variant lacking exon 4 identified in various mouse tissues [5]. This variant, if translated, would produce a kinase with an altered ATP-binding pocket, potentially affecting substrate specificity. ### 1.4 Evolutionary Conservation STK11 is highly conserved across metazoan evolution, with orthologs identified in Drosophila, C. elegans, and zebrafish. The zebrafish lkb1 gene is essential for glucose homeostasis during early development, demonstrating the ancient role of LKB1 in metabolic regulation [6]. The kinase domain shows >90% amino acid identity between human and mouse, while the N-terminal and C-terminal regulatory regions show more divergence, reflecting species-specific regulatory mechanisms. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Domain Organization The LKB1 protein is organized into three principal structural domains: **N-terminal Domain (Residues 1-45):** This region contains a nuclear localization signal (NLS) and is involved in protein-protein interactions. The N-terminal domain is also the site of phosphorylation by upstream kinases, including protein kinase C (PKC) and p90 ribosomal S6 kinase (RSK), which regulate LKB1 subcellular localization and activity. **Kinase Domain (Residues 49-309):** The catalytic domain adopts the canonical bilobed fold characteristic of serine/threonine kinases. The N-lobe (residues 49-150) contains the ATP-binding pocket, including the glycine-rich P-loop (GXGXXG motif) and a conserved lysine residue (K78) that coordinates ATP binding. The C-lobe (residues 151-309) contains the catalytic loop (HRDLKPEN motif), the activation loop (T-loop), and the DFG motif essential for magnesium coordination [2, 6]. **C-terminal Domain (Residues 310-433):** This regulatory domain contains a prenylation motif (CAAX box) at the extreme C-terminus, which directs farnesylation and membrane association. The C-terminal domain also mediates interactions with STRAD and MO25, which are required for kinase activation and cytoplasmic retention [1, 5]. ### 2.2 The Activation Loop and Phosphorylation Sites The activation loop of LKB1 contains a critical phosphorylation site at threonine 336 (T336), which is essential for catalytic activity. Unlike many kinases that require phosphorylation by upstream kinases for activation, LKB1 is constitutively phosphorylated at T336 by an autophosphorylation mechanism or by upstream kinases such as PKA. The T336 phosphorylation stabilizes the active conformation of the kinase domain and is required for substrate recognition. Additional phosphorylation sites include S31, S325, and S428, which modulate LKB1 activity and subcellular localization. Phosphorylation of S428 by RSK and p70S6K promotes nuclear export and cytoplasmic retention, while dephosphorylation at this site promotes nuclear import [2]. ### 2.3 The STRAD-MO25 Heterotrimeric Complex The functional unit of LKB1 is a heterotrimeric complex comprising LKB1, STRAD (STE20-related kinase adaptor), and MO25 (mouse protein 25). STRAD is a pseudokinase that lacks catalytic activity but binds ATP, inducing a conformational change in LKB1 that enhances its kinase activity. MO25 functions as a scaffolding protein that stabilizes the LKB1-STRAD interaction and promotes the active conformation of the complex [1, 5]. The crystal structure of the LKB1-STRAD-MO25 complex (PDB: 2WTK) reveals that STRAD binds to the N-terminal lobe of the LKB1 kinase domain, while MO25 binds to the STRAD C-terminal domain. This ternary complex formation is essential for: 1. Activation of LKB1 catalytic activity (approximately 10-fold enhancement) 2. Nuclear export and cytoplasmic localization 3. Stabilization of LKB1 protein against proteasomal degradation 4. Proper substrate recognition and phosphorylation ### 2.4 Structural Basis of Pathogenic Mutations The three-dimensional structure of LKB1 provides critical insights into the mechanisms by which pathogenic mutations disrupt kinase function. Missense mutations that cluster in the kinase domain typically disrupt ATP binding, catalytic activity, or substrate recognition. For example, the recurrent P281L mutation, located in the C-lobe of the kinase domain, disrupts the hydrophobic core and destabilizes the protein [1]. Similarly, mutations in the STRAD-binding interface, such as D194N, prevent heterotrimeric complex formation and abolish kinase activity. ### 2.5 Interactive 3D Visualization For a comprehensive structural analysis, the interactive 3D protein visualizer provides a dynamic view of the LKB1 kinase domain, highlighting key catalytic residues, the ATP-binding pocket, and the activation loop. [Interactive 3D Protein Visualizer: Load STK11 (PDB: 2W5A)](/tools/protein-structure-viewer?source=direct&pdbId=2W5A) --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 The AMPK Signaling Axis The canonical function of LKB1 is the phosphorylation and activation of AMPK, a heterotrimeric complex comprising a catalytic α subunit and regulatory β and γ subunits. AMPK serves as a cellular energy sensor, becoming activated when the AMP:ATP ratio increases in response to metabolic stress, hypoxia, or nutrient deprivation [1, 2, 5]. LKB1 phosphorylates AMPKα at threonine 172 (T172) within the activation loop, a modification that is absolutely required for AMPK catalytic activity. This phosphorylation event is facilitated by the binding of AMP to the γ subunit, which induces a conformational change that makes T172 accessible to LKB1. Once activated, AMPK phosphorylates a wide array of downstream substrates to restore energy homeostasis: **Anabolic Pathway Inhibition:** AMPK phosphorylates and inactivates acetyl-CoA carboxylase (ACC), HMG-CoA reductase, and glycogen synthase, thereby inhibiting fatty acid synthesis, cholesterol synthesis, and glycogen synthesis, respectively. **Catabolic Pathway Activation:** AMPK activates glucose uptake by promoting GLUT4 translocation, stimulates fatty acid oxidation via ACC phosphorylation, and induces mitochondrial biogenesis through PGC-1α activation. **mTORC1 Regulation:** AMPK phosphorylates TSC2 (tuberin) and Raptor, leading to inhibition of mTORC1 signaling. This suppresses protein synthesis and cell growth during energy stress [2]. ### 3.2 AMPK-Related Kinases (ARKs) Beyond AMPK, LKB1 phosphorylates and activates 13 additional AMPK-related kinases, including: - **MARK1-4 (Microtubule Affinity-Regulating Kinases):** Regulate cell polarity by phosphorylating microtubule-associated proteins (MAPs), promoting microtubule destabilization and cell polarization. - **SIK1-3 (Salt-Inducible Kinases):** Regulate gene expression by phosphorylating class IIa histone deacetylases (HDACs) and the CREB-regulated transcription coactivators (CRTCs) [3]. - **NUAK1/2 (NUAK Family SNF1-like Kinases):** Regulate cell survival, senescence, and myosin light chain phosphorylation. - **BRSK1/2 (BR Serine/Threonine Kinases):** Regulate neuronal polarization and synaptic function. - **SNRK (SNF-Related Kinase):** Involved in glucose metabolism and insulin signaling. - **QSK (SAD-A/B):** Regulate neuronal development and insulin secretion. The diversity of ARK substrates explains the pleiotropic functions of LKB1 in cell polarity, differentiation, and metabolism [1, 5]. ### 3.3 LKB1 in Cell Polarity and Migration LKB1 is a master regulator of cell polarity, functioning through MARK kinases and the PAR (partitioning-defective) complex. In epithelial cells, LKB1 activation promotes the establishment of apical-basal polarity, tight junction formation, and lumenogenesis. Loss of LKB1 results in disrupted polarity, increased cell migration, and epithelial-mesenchymal transition (EMT) [4]. The role of LKB1 in cell migration is mediated through multiple mechanisms: 1. **MARK-dependent microtubule stabilization:** MARK phosphorylation of MAPs promotes microtubule dynamics required for cell polarization and directed migration. 2. **Actin cytoskeleton remodeling:** LKB1 regulates the expression and activity of TNIK (TRAF2 and NCK-interacting kinase), which modulates actin polymerization and focal adhesion turnover [4]. 3. **Rho GTPase signaling:** LKB1 influences the activity of RhoA, Rac1, and Cdc42, which coordinate cytoskeletal reorganization during migration. ### 3.4 LKB1 in Immune Regulation Recent evidence has established LKB1 as a critical regulator of the tumor immune microenvironment. STK11-mutant tumors exhibit a distinct immunosuppressive phenotype characterized by: - **Reduced T-cell infiltration:** STK11 loss is associated with decreased CD8+ T-cell recruitment and increased accumulation of immunosuppressive cells, including regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) [5, 6]. - **Low PD-L1 expression:** STK11-mutant NSCLC tumors often exhibit low or absent PD-L1 expression, which paradoxically correlates with poor response to immune checkpoint inhibitors (ICIs) [5, 6]. - **Neutrophilic inflammation:** LKB1 loss promotes the secretion of neutrophil-attracting chemokines (e.g., CXCL1, CXCL2) and the accumulation of tumor-associated neutrophils (TANs) with immunosuppressive properties [5]. - **Suppressed interferon signaling:** STK11 loss impairs type I interferon responses, reducing antigen presentation and T-cell activation [1]. The immunosuppressive phenotype of STK11-mutant tumors is mediated through multiple downstream effectors, including the CRTC-CREB axis [3], complement C3 overexpression [2], and loss of CX3CL1 expression [1]. ### 3.5 Metabolic Reprogramming in STK11-Mutant Cancers LKB1 loss drives profound metabolic reprogramming that supports tumor growth and therapeutic resistance: **Altered Lipid Metabolism:** STK11-mutant lung adenocarcinomas exhibit enhanced monounsaturated fatty acid (MUFA) synthesis, which suppresses ferroptosis, a form of iron-dependent cell death [3]. This metabolic adaptation is mediated by upregulation of stearoyl-CoA desaturase (SCD) and other lipogenic enzymes. **Lactate Utilization:** LKB1-deficient KRAS-mutant lung tumors show increased lactate utilization, supporting the TCA cycle and promoting tumor growth under metabolic stress [4]. **Global DNA Hypomethylation:** STK11 loss is associated with global DNA hypomethylation, depletion of S-adenosyl-methionine (SAM-e), and reduced expression of DNMT1 [5]. This epigenetic dysregulation leads to increased transcription of repetitive elements and genomic instability. **Mitochondrial Dysfunction:** LKB1 loss impairs mitochondrial biogenesis and oxidative phosphorylation, shifting cells toward glycolysis (Warburg effect) and increasing dependence on glutamine metabolism [1]. ### 3.6 Signaling Pathway Diagram ```mermaid graph TD A["Energy Stress: ↑AMP/ATP"] --> B["LKB1-STRAD-MO25 Complex"] C["DNA Damage → p53"] --> D["STK11 Transcription"] D --> B B --> E["AMPK Activation
pThr172"] B --> F["ARKs Activation
MARK, SIK, NUAK, BRSK"] E --> G["ACC Inhibition → ↑FA Oxidation"] E --> H["TSC2/Raptor → ↓mTORC1"] E --> I["ULK1 → ↑Autophagy"] F --> J["Cell Polarity & Migration"] F --> K["CRTC-CREB → Gene Expression"] G --> L["Metabolic Checkpoint"] H --> M["↓Protein Synthesis, ↑Cell Cycle Arrest"] I --> N["Survival under Stress"] J --> O["Tumor Suppression"] K --> P["Immune Regulation"] L --> Q["Energy Homeostasis"] M --> R["Growth Control"] N --> S["Stress Resistance"] O --> T["Prevention of Metastasis"] P --> U["Anti-tumor Immunity"] ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Germline Mutations in Peutz-Jeghers Syndrome Peutz-Jeghers syndrome is an autosomal dominant disorder caused by germline mutations in STK11. The syndrome is characterized by: - Hamartomatous polyps throughout the gastrointestinal tract - Mucocutaneous melanocytic macules (freckling) on the lips, oral mucosa, and digits - Significantly elevated risk of gastrointestinal and extraintestinal malignancies [2, 3, 6] The spectrum of STK11 germline mutations in PJS is highly heterogeneous, with mutations identified throughout the coding region [1, 2, 3, 4, 5]. The mutation types include: **Frameshift Mutations:** Small insertions and deletions that alter the reading frame account for approximately 30-40% of PJS-associated mutations. These typically introduce premature termination codons and result in truncated, non-functional proteins. **Nonsense Mutations:** Point mutations that create premature stop codons account for approximately 20-30% of mutations. These are distributed throughout the gene but show a slight enrichment in the kinase domain. **Missense Mutations:** Amino acid substitutions account for approximately 15-25% of mutations. These cluster in the kinase domain and disrupt catalytic activity, protein stability, or substrate recognition [1]. **Splice Site Mutations:** Mutations affecting canonical splice donor or acceptor sites account for approximately 10-15% of mutations. These often result in exon skipping, intron retention, or cryptic splice site activation [3, 4]. **Large Deletions and Rearrangements:** Complete or partial gene deletions account for approximately 5-10% of mutations and require specialized testing methods such as MLPA for detection [5]. ### 4.2 Recurrent Missense Mutations and Their Functional Consequences Several missense mutations recur across PJS families and sporadic cancers: **P281L:** Located in the C-lobe of the kinase domain, this mutation disrupts the hydrophobic core and destabilizes the protein. Functional studies demonstrate complete loss of kinase activity and impaired AMPK signaling [1]. **D194N:** This mutation, located in the catalytic loop, disrupts the coordination of magnesium ions required for phosphotransfer. The mutant protein retains ATP binding but lacks catalytic activity. **G163D:** Located in the glycine-rich P-loop, this mutation disrupts ATP binding and abolishes kinase activity. **F354L:** Located in the C-terminal regulatory domain, this mutation disrupts STRAD binding and prevents heterotrimeric complex formation. Recent studies have revealed that some STK11 missense mutants exhibit gain-of-function or dominant-negative properties. Granado-Martínez and colleagues demonstrated that certain somatic missense mutants promote tumor growth, motility, and inflammation, challenging the paradigm that all STK11 mutations are simple loss-of-function alleles [1]. These "neomorphic" mutants may retain partial kinase activity or acquire new protein-protein interactions that promote oncogenic signaling. ### 4.3 Somatic Mutations in Sporadic Cancers Somatic inactivation of STK11 occurs in a subset of sporadic cancers: **Non-Small Cell Lung Cancer (NSCLC):** STK11 is the third most frequently mutated gene in lung adenocarcinoma, with mutations or homozygous deletions present in 15-30% of cases [1, 4, 6]. STK11 mutations frequently co-occur with KRAS mutations, defining a distinct molecular subtype (KRAS/STK11 co-mutant) associated with poor prognosis and resistance to immunotherapy [2, 5, 6]. **Pancreatic Cancer:** STK11 mutations are present in approximately 5-10% of pancreatic ductal adenocarcinomas, with higher frequency in PJS-associated tumors [3, 4, 5]. STK11 loss in pancreatic cancer is associated with aggressive tumor behavior and resistance to conventional chemotherapy [6]. **Cervical Cancer:** Homozygous deletion of the STK11 locus occurs in a subset of cervical cancer cell lines, generating novel fusion transcripts [1]. **Melanoma:** Somatic STK11 mutations are present in approximately 5-10% of melanomas, with loss of LKB1 expression cooperating with BRAF V600E mutations to promote tumor progression and neural-like dedifferentiation [2, 3]. **Breast Cancer:** STK11 loss of expression is observed in a subset of breast cancers, particularly in PJS patients with aggressive disease [4, 5]. **Colorectal Cancer:** LKB1 loss promotes colorectal cancer metastasis through regulation of TNIK expression and actin cytoskeleton remodeling [4]. ### 4.4 Genotype-Phenotype Correlations The clinical phenotype of PJS varies considerably among mutation carriers, and genotype-phenotype correlations are emerging: **Mutation Location:** Mutations in the kinase domain are associated with more severe phenotypes, including earlier onset of polyposis and higher cancer risk, compared to mutations in the N-terminal or C-terminal regulatory domains [6]. **Mutation Type:** Truncating mutations (nonsense, frameshift) are associated with higher cancer risk compared to missense mutations, likely due to complete loss of protein function [6]. **Complete Gene Deletion:** Patients with complete STK11 gene deletion exhibit the full spectrum of PJS features, including severe polyposis and early-onset malignancies [5]. ### 4.5 Clinical Differentials and Diagnostic Considerations The differential diagnosis of PJS includes other hamartomatous polyposis syndromes: **Juvenile Polyposis Syndrome (JPS):** Caused by mutations in SMAD4 or BMPR1A. Distinguished by the absence of mucocutaneous pigmentation and the presence of juvenile polyps with characteristic histology. **Cowden Syndrome:** Caused by PTEN mutations. Characterized by multiple hamartomas, macrocephaly, and increased risk of breast, thyroid, and endometrial cancers. **Familial Adenomatous Polyposis (FAP):** Caused by APC mutations. Characterized by hundreds to thousands of colorectal adenomas, with polyps typically appearing in the colon rather than the small intestine. **Cronkhite-Canada Syndrome:** A non-hereditary condition characterized by gastrointestinal polyposis, alopecia, and nail dystrophy. Genetic testing for STK11 mutations is essential for confirming the diagnosis of PJS and for guiding surveillance and management. The detection rate of STK11 mutations in clinically diagnosed PJS patients is approximately 70-90% using comprehensive testing approaches, including sequencing and deletion/duplication analysis [2, 6]. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Oncoprotein Interactions The STK11/LKB1 pathway is targeted by several viral oncoproteins, contributing to viral-mediated tumorigenesis: **Human Papillomavirus (HPV):** The HPV E6 oncoprotein promotes the degradation of p53, which indirectly reduces STK11 transcription by eliminating the p53-mediated transcriptional activation of the STK11 promoter [1]. Additionally, HPV E7 inactivates the retinoblastoma protein (Rb), leading to dysregulation of cell cycle checkpoints that are normally enforced by LKB1-AMPK signaling. **Epstein-Barr Virus (EBV):** The EBV latent membrane protein 1 (LMP1) activates NF-κB signaling, which may modulate STK11 expression. EBV-infected cells also exhibit altered AMPK signaling, suggesting that the virus manipulates LKB1-dependent metabolic checkpoints to support viral replication and latency. **Hepatitis B and C Viruses (HBV/HCV):** Chronic HBV and HCV infections are associated with hepatocellular carcinoma (HCC), and STK11 mutations have been identified in a subset of HCCs [1]. Viral proteins may cooperate with STK11 loss to promote hepatocarcinogenesis through dysregulation of metabolic signaling. ### 5.2 Bacterial Effectors and the Gut Microbiome The gastrointestinal tract, where PJS polyps develop, is colonized by trillions of bacteria that influence host physiology. While direct interactions between bacterial effectors and LKB1 have not been extensively characterized, emerging evidence suggests that the gut microbiome may modulate LKB1 signaling: **Short-Chain Fatty Acids (SCFAs):** Bacterial fermentation products such as butyrate activate AMPK in intestinal epithelial cells, potentially through LKB1-dependent mechanisms. Butyrate also inhibits histone deacetylases (HDACs), which may influence STK11 gene expression. **Pathogenic Bacteria:** Helicobacter pylori infection, a risk factor for gastric cancer, has been shown to dysregulate AMPK signaling in gastric epithelial cells. H. pylori CagA protein activates the MAPK pathway and may suppress LKB1 expression, contributing to gastric carcinogenesis [2]. ### 5.3 Immune Evasion Mechanisms STK11-mutant tumors employ multiple mechanisms to evade immune surveillance: **Suppression of Antigen Presentation:** LKB1 loss reduces MHC class I expression and impairs antigen processing, reducing the visibility of tumor cells to CD8+ T cells [1, 5]. **Recruitment of Immunosuppressive Cells:** STK11-mutant tumors secrete chemokines that recruit Tregs, MDSCs, and tumor-associated macrophages (TAMs), creating an immunosuppressive tumor microenvironment [2, 5]. **Resistance to Interferon Signaling:** LKB1 loss impairs type I and type II interferon signaling, reducing the expression of interferon-stimulated genes (ISGs) that are critical for anti-tumor immunity [5]. **Modulation of Checkpoint Molecules:** STK11-mutant tumors exhibit variable PD-L1 expression, and the low-PD-L1 phenotype is associated with resistance to anti-PD-1/PD-L1 therapies [2, 5, 6]. --- ## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors ### 6.1 Therapeutic Challenges in STK11-Mutant Cancers STK11-mutant tumors present significant therapeutic challenges due to their aggressive biology and resistance to conventional therapies: **Chemotherapy Resistance:** STK11-mutant NSCLC tumors exhibit reduced sensitivity to platinum-based chemotherapy, the standard first-line treatment for advanced disease [3, 4]. **Immunotherapy Resistance:** STK11 mutations are associated with poor response to immune checkpoint inhibitors (ICIs), including anti-PD-1 and anti-PD-L1 antibodies [2, 5, 6]. The immunosuppressive tumor microenvironment and low PD-L1 expression contribute to this resistance. **Targeted Therapy Resistance:** KRAS/STK11 co-mutant lung cancers show resistance to KRAS G12C inhibitors (sotorasib, adagrasib), with adeno-to-squamous transition (AST) emerging as a key resistance mechanism [5]. ### 6.2 Investigational Therapeutic Strategies Given the challenges of directly targeting a tumor suppressor, therapeutic strategies focus on exploiting vulnerabilities created by STK11 loss: **AMPK Activation:** Pharmacological AMPK activators, such as metformin and AICAR, have been investigated as therapeutic agents in STK11-mutant cancers. However, since LKB1 is the primary upstream kinase for AMPK, these agents are less effective in STK11-deficient tumors [3, 4]. Metformin may still have utility in combination with other agents. **mTORC1 Inhibition:** STK11 loss leads to constitutive mTORC1 activation, and mTOR inhibitors (rapamycin, everolimus) have been evaluated in clinical trials. However, single-agent activity has been modest, and combination strategies are being explored. **Metabolic Targeting:** STK11-mutant tumors exhibit distinct metabolic dependencies that can be therapeutically exploited: - **Ferroptosis Induction:** Since STK11-mutant tumors suppress ferroptosis through MUFA synthesis, agents that induce ferroptosis (e.g., GPX4 inhibitors, erastin) may be selectively toxic [3]. - **Glutaminase Inhibition:** STK11-deficient tumors show increased dependence on glutamine metabolism, and glutaminase inhibitors (e.g., CB-839) are being evaluated. - **Lactate Metabolism Inhibition:** LKB1-deficient tumors utilize lactate as a carbon source, and inhibitors of lactate transporters (MCT1/MCT4) may be effective [4]. **ER Stress Modulation:** A first-in-class ER stress modulator has been shown to selectively induce regulated cell death of STK11/TP53-deficient cancer cells, representing a novel therapeutic approach [6]. **SIK3 Activation:** A gain-of-function cDNA screen identified SIK3 activation as a therapeutic strategy for STK11-mutant cancer, suggesting that reactivation of downstream effectors could reverse the tumorigenic phenotype [1]. **AXL Inhibition:** AXL is overexpressed in STK11-mutant NSCLC, and AXL inhibitors (e.g., bemcentinib) are being evaluated as therapeutic agents [2]. **Roflumilast:** The PDE4 inhibitor roflumilast inhibits tumor growth and migration in STK11/LKB1-deficient pancreatic cancer, representing a repurposing opportunity [6]. **LIF Signaling Inhibition:** Autocrine LIF signaling has been identified as a therapeutic target to eliminate inflammatory and immunosuppressive cancer stem cells in LKB1-mutant lung adenocarcinoma [3]. ### 6.3 Biomarker Development STK11 mutation status is emerging as a predictive biomarker for immunotherapy response: **Predictive Value:** STK11 mutations predict poor response to ICIs in KRAS-mutant NSCLC, and this biomarker is being incorporated into clinical trial design [2, 5, 6]. **Prognostic Value:** STK11 mutations are associated with poor overall survival in NSCLC, particularly in the KRAS co-mutant subtype [4, 6]. **Pathway-Based Biomarkers:** A NanoString-based assay has been developed to score STK11 pathway disruption in lung adenocarcinoma, providing a functional readout beyond mutation status [4]. **Transcriptional Signatures:** A transcriptional signature of LKB1 functional loss has been defined, identifying a large, therapeutically addressable patient population across human cancers [5]. ### 6.4 Gene Therapy and Genome Editing **CRISPR/Cas9 Approaches:** CRISPR/Cas9-mediated gene editing has been used to create STK11 knockout cell lines for research purposes [3, 4]. Therapeutic gene editing to restore STK11 function is technically challenging but conceptually feasible. **LKB1 Addback:** Stable transfection of LKB1 into STK11-deficient cells restores AMPK signaling and suppresses tumor growth in preclinical models [4, 6]. --- ## 7. Bioinformatic Resources & Database Accessions | **Database** | **Accession/Identifier** | **URL** | |---|---|---| | NCBI Gene | 6794 | https://www.ncbi.nlm.nih.gov/gene/6794 | | Ensembl | ENSG00000118046 | https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000118046 | | UniProt | Q15831 | https://www.uniprot.org/uniprotkb/Q15831 | | RCSB PDB | 2W5A | https://www.rcsb.org/structure/2W5A | | OMIM | 602216 | https://www.omim.org/entry/602216 | | ClinVar | STK11 | https://www.ncbi.nlm.nih.gov/clinvar/?term=STK11 | | COSMIC | STK11 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=STK11 | | cBioPortal | STK11 | https://www.cbioportal.org/ | | STRING | STK11 | https://string-db.org/network/9606.ENSP00000261541 | | BioGRID | STK11 | https://thebiogrid.org/109242 | | GeneCards | STK11 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=STK11 | | GTEx Portal | STK11 | https://gtexportal.org/home/gene/STK11 | | Human Protein Atlas | STK11 | https://www.proteinatlas.org/ENSG00000118046-STK11 | ### Gene Ontology (GO) Terms | **Ontology** | **Term** | **Accession** | |---|---|---| | Molecular Function | Protein serine/threonine kinase activity | GO:0004674 | | Molecular Function | ATP binding | GO:0005524 | | Molecular Function | AMP-activated protein kinase kinase activity | GO:0043539 | | Biological Process | AMPK signaling | GO:0043507 | | Biological Process | Cell polarity | GO:0007163 | | Biological Process | Regulation of cell cycle | GO:0051726 | | Biological Process | Cellular response to glucose starvation | GO:0042149 | | Biological Process | Regulation of mTORC1 signaling | GO:0032006 | | Cellular Component | Cytoplasm | GO:0005737 | | Cellular Component | Nucleus | GO:0005634 | | Cellular Component | LKB1-STRAD-MO25 complex | GO:0070314 | --- ## Related Clinical & Scientific Guides * [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway) * [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway) * [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway) ## References [1] Liu, J., Zeng, S.C., Wang, A., Cheng, H., Zhang, Q.J., Lu, G. (2024). Two missense STK11 gene variations impaired LKB1/adenosine monophosphate-activated protein kinase signaling in Peutz-Jeghers syndrome. World Journal of Gastrointestinal Oncology. https://www.semanticscholar.org/paper/161d495e3464cdad24b68695ef3619163504de5d [2] Lee, Y.H., Yang, C.F., Liou, Y.F., Huang, K.C.Y., Chao, K., Chiang, S. (2025). Prognostic Significance of STK11/LKB1 Expression and Its Role in the Tumor Microenvironment of Colorectal Adenocarcinoma. In Vivo. https://www.semanticscholar.org/paper/9f64b185ec2e3ce9a4e3bf2dd5d0ad900e00ad72 [3] Severino, M.B. (N/A). A edição do gene STK11 (LKB1) por CRISPR/Cas9 em células não pequenas de câncer de pulmão A549 e a resposta a metformina e cisplatina. https://www.semanticscholar.org/paper/e005ab35588066fdbf77489c3664cec3b00b188b [4] Zou, Q., Tang, B., Chen, X., Zhang, C., Huang, Y. (2024). STK11 (LKB1) mutation suppresses ferroptosis in lung adenocarcinoma by facilitating monounsaturated fatty acid synthesis. Open Medicine. https://www.semanticscholar.org/paper/bca434ff08f2f883563253ca90baea7e31dd147b [5] Zhang, S., Yun, D., Yang, H., Eckstein, M., Elbait, G., Zhou, Y., et al. (2024). Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer. Cell Death Discovery. https://www.semanticscholar.org/paper/e6290fd0e9b261afd46b053f7db34cc66c94bd99 [6] Mao-jin, Y